In the last trading session, 1.96 million shares of the Mereo Biopharma Group Plc ADR (NASDAQ:MREO) were traded, and its beta was 0.55. Most recently the company’s share price was $1.90, and it changed around -$0.05 or -2.56% from the last close, which brings the market valuation of the company to $294.78M. MREO currently trades at a discount to its 52-week high of $5.02, offering almost -164.21% off that amount. The share price’s 52-week low was $1.58, which indicates that the current value has risen by an impressive 16.84% since then. We note from Mereo Biopharma Group Plc ADR’s average daily trading volume that its 10-day average is 1.97 million shares, with the 3-month average coming to 1.37 million.
Mereo Biopharma Group Plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.11. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended MREO as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Mereo Biopharma Group Plc ADR is expected to report earnings per share of -0.01 for the current quarter.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Instantly MREO has showed a red trend with a performance of -2.56% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.9900 on recent trading dayincreased the stock’s daily price by 4.52%. The company’s shares are currently down -45.71% year-to-date, but still up 3.83% over the last five days. On the other hand, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is -27.48% down in the 30-day period. We can see from the shorts that 6.54 million shares have been sold at a short interest cover period of 4.99 day(s).
The consensus price target as assigned by Wall Street analysts is $7.5, which translates to bulls needing to increase their stock price by 74.67% from its current value. Analyst projections state that MREO is forecast to be at a low of $4 and a high of $8.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 11.89M in revenue for the current quarter. 7 analysts expect Mereo Biopharma Group Plc ADR to make 4.93M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 34.82%. Mereo Biopharma Group Plc ADR earnings are expected to increase by 26.19% in 2025, but the outlook is positive 17.79% per year for the next five years.
MREO Dividends
Mereo Biopharma Group Plc ADR’s next quarterly earnings report is expected to be released on 2025-Mar-25.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.99% of Mereo Biopharma Group Plc ADR shares, and 75.04% of them are in the hands of institutional investors. The stock currently has a share float of 75.79%. Mereo Biopharma Group Plc ADR stock is held by 100.0 institutions, with RUBRIC CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 2.1506% of the shares, which is about 15.31 million shares worth $55.11 million.
ADAGE CAPITAL PARTNERS GP, L.L.C., with 1.6566% or 11.79 million shares worth $42.45 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund and Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF were the top two Mutual Funds as of Feb 28, 2025 . The former held 759.1 shares worth $1.44 million, making up 0.10% of all outstanding shares. On the other hand, Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF held roughly 524.03 shares worth around $1.0 million, which represents about 0.07% of the total shares outstanding.
